A Generic Medicines Sector View on Sustainable Development in Pharmaceuticals

1
(No Transcript)
2
A Generic Medicines Sector View on Sustainable
Development in Pharmaceuticals

• Uppsala, 10 Nov 2009
• Sean Bowler
• VP Engineering and EHS, Actavis

3
Contents

• The European Generic medicines Association
  Generic Medicines
• Medicinal Product Life Cycle
• Specific Challenges for the Generic Sector
• Actavis How one company manages EHS
• Way forward

4
The European Generic medicines Association (EGA)

5
The EGA Generic Medicines

• EGA represents over 700 companies in 34
  European countries
• Generic medicines companies employ over 130,000
  people in the EU
• Generic medicines account for nearly 50 of packs
  dispensed in the EU and 18 of pharmaceutical
  expenditure

5
6
Generic Medicines- Key Healthcare Provider

• Committed to Healthcare and Improvement of Life
  Health Quality
• Mature and responsible pharmaceutical sector
• Ensuring access to high-quality affordable
  medicines

6
7
Medicinal PRODUCT LIFE CYCLE

8
Traditional Product Life Cycle
8
9
Product Life Cycle, Pharmaceutical Industry
9
10
Product Life Cycle, Pharmaceutical Industry
10
11
Advantages and Challenges specific to generic
medicines
ADVANTAGES
RESULTING CHALLENGES

• Established Product (Up to 20 years history)
• Proven Equivalence
• Low Cost Supply
• Greater availability

• Process Chemistry
• Costs
• Raw materials
• Manufacturing
• Control of the Value Chain

Life-cycle Management, Outsourcing to non-EU
countries, Operationalising Sustainability,
Minimising the environmental impact of the
business.
11
12
Actavis
EHS OVERVIEW PRESENTATION
13
Actavis Environmental,Health Safety (EHS)
Policy

• Actavis is committed to operating all aspects of
  its business in a safe and responsible manner
  that protects the environment, and promotes the
  health welfare of employees and the communities
  we operate in.

13
14
Actavis EHS Commitment- Action Plan

• Establish monitor ambitious objectives and
  targets to prevent occupational injury, illness
  or environmental pollution
• Proactively manage our EHS risks to ensure
  compliance with all applicable legal and other
  requirements
• Operate efficiently by integrating EHS
  considerations into our planning and decision
  making
• Use our flexibility to continuously improve our
  EHS performance
• Openly communicate our goals and performance to
  all stakeholders, including customers
• Work together as a team to promote a positive
  culture where every employee accepts personal
  responsibility for EHS

14
15
Actavis EHS Policy Reflected in Strategic
Objectives

• To fulfil our EHS policy and achieve the vision
  outlined therein, the following strategic
  priorities direct our efforts
• Improve the Actavis injury illness rate, and
  environmental performance
• Reduce EHS risks in all Actavis operations
• Achieve 100 compliance
• Integrate EHS into the way we do business
• Continuously improve EHS performance

15
16
Strategy implementation Actavis Environmental,
Health Safety (EHS)
HOW
STRATEGIC OBJECTIVES

• Continuously improve our incident rate
• Reduce EHS risks
• Achieve 100 compliance
• Implement an independently verifiable EHS
  management system across all operating sites
• Continuously improve EHS performance

• Metrics
• Proactive
• Reactive
• Focussed strategic initiatives.
• Independent Certification
• Training
• Auditing program

16
17
Actavis EHS - Performance Control Cycle / PDCA
loop
Set Objectives
Take Corrective action
Continue
Measure
Review progress
17
18
Actavis EHS - Goal Setting
18
19

• Advances in science and technology have
  brought us tremendous improvements in areas like
  medicineFor all the advantages we have gained
  from our new technologies, we have also witnessed
  many unanticipated side effects.

P.232. AN INCONVENIENT TRUTH, Al Gore. 2006
19
20
Way forward...

• The EGA is committed to concrete action
• Providing access to high-quality medicines
  produced in conditions minimising the
  environmental footprint and managed through
  their life-cycle
• Support EU sustainability initiatives aimed at
  fostering Environment, Health and Safety
  excellence in the pharmaceutical sector

20
21

• Thank you!
• Sean Bowler
• Actavis
• sebowler_at_actavis.com